Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Top Cited Papers
Open Access
- 1 July 2006
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 10 (1), 39-50
- https://doi.org/10.1016/j.ccr.2006.05.024
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins β1 and β2Developmental Biology, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004
- Differential Shedding of Transmembrane Neuregulin Isoforms by the Tumor Necrosis Factor-α-Converting EnzymeMolecular and Cellular Neuroscience, 2000
- An Essential Role for Ectodomain Shedding in Mammalian DevelopmentScience, 1998
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Autocrine and paracrine growth regulation of breast cancer: Clinical implicationsBreast Cancer Research and Treatment, 1990
- Autocrine Secretion and Malignant Transformation of CellsNew England Journal of Medicine, 1980